A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

This practice is not approved by the U.S. Food and Drug Administration (FDA). "Health care clinicians do not typically ... a ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers ...

"Because most people with obesity have elevated insulin levels, they develop insulin resistance, which contributes to weight gain. Semaglutide (or Ozempic) helps lower the levels of this fat-storing ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...